According to reports from Business Standard, Verlinvest is accelerating its India investments as the Belgian evergreen investment firm targets convenience-driven, value-focused consumer brands in healthcare, wellness, and quick commerce. The firm, which manages more than €3 billion in assets globally, has backed 25 Indian consumer brands over 15 years, exiting 16 companies while currently holding stakes in nine companies including Blue Tokai Coffee Roasters, Epigamia, and The Eye Foundation. Deal sizes in India typically range from $20 million to $100 million.
As reported by Business Standard, India's consumer market in 2026 faces three simultaneous pressures: Middle East-driven inflationary risk, AI-fuelled caution among white-collar consumers, and the rapid rise of quick commerce. Managing Director and Head of Asia Arjun Anand noted that the war in the Middle East continues to be a serious concern and can potentially create hugely inflationary headwinds for India, with rising oil prices affecting supply chains. However, he emphasized that quick commerce is emerging as a key tailwind for brands, particularly those offering convenience plus value packaging.
According to Business Standard, Anand acknowledged that the current environment is unfavorable for exits, stating that global news and circumstances keep changing day by day. The firm partially exited Wakefit, Purplle, and Sula Vineyards between 2020 and 2025 when market conditions were favorable, but Anand indicated that if the cycle today changes because of volatility, then we will aim to hold through the volatility and not exit. He explained that while closed-ended funds often lack flexibility to wait out cycles, Verlinvest relies on three primary exit routes: strategic acquisitions, secondary stake sales, and public listings.
As reported by Business Standard, Verlinvest has been expanding its portfolio into consumer healthcare, with hospitals and single-speciality clinics increasingly establishing themselves as trusted consumer brands. The firm has invested in The Eye Foundation and Ferty9 Fertility Center, citing strong tailwinds driven by rising insurance penetration, premiumisation of quality care, and limited healthcare infrastructure relative to demand. Anand confirmed that the firm's focus is going to be limited to consumer healthcare, with no plans to invest in B2B medical businesses or companies serving healthcare providers.
According to Business Standard, AI presents mixed implications for Verlinvest's strategy, serving as both a consumer headwind and business opportunity. Anand noted that AI is making white-collar consumers more cautious about discretionary spending amid job security fears, while AI tools enable smaller brands to better understand consumer preferences and deliver more personalised products. However, he warned that brands are not as durable as they used to be two decades ago as digital personalisation allows emerging brands to target niche audiences more effectively. Looking ahead, Anand identified vitamins, minerals, and supplements as underpenetrated categories, and hydration products as a promising category gaining global traction but still nascent in India.
